Complaint Against All Defendants , Filed by Harry Speaks. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form, # 3 Attachment A)(Benton, Danae)

Document #1 Filed 03/27/2026 · 11 pages · District Court, E.D. Pennsylvania · View original PDF

1Full (first, middle, and last) name of Plaintiff injured/deceased due to use of GLP- 1 RA Product(s):

2If applicable, full name(s) and representative capacity of Plaintiff(s) alleging wrongful death claim:

of the estate of , deceased.

3If applicable, full name(s) of Plaintiff(s) alleging survival claims, as permitted under state law(s):

4If applicable, full name(s) of Plaintiff(s) alleging loss of consortium or loss of services: Defendant(s)

5Plaintiff(s)/Decedent’s Representative is/are suing the following Defendant(s) (check all that apply):

Novo Nordisk Inc. Novo Nordisk A/S Eli Lilly and Company Lilly USA, LLC other(s) (identify): Harry Speaks

✔ ✔

JURISDICTION AND VENUE

6City and state of Plaintiff(s)’ current residence (or in a case brought on behalf of a Decedent, Decedent’s last permanent residence):

7State where Plaintiff/Decedent was prescribed the GLP-1RA Product(s) at issue:

8State of Plaintiff’s/Decedent’s residence at time of their use of the GLP-1RA Product(s) at issue:

9City and state of Plaintiff(s)’/Decedent’s residence at time of diagnosis of injury:

10Jurisdiction is based on:

diversity of citizenship pursuant to 28 U.S.C. § 1332 other (plead in sufficient detail as required by applicable rules):

11The District Court(s) where Plaintiff(s) might have otherwise filed this Short Form Complaint, absent this Court’s CMO No. 14, and/or to where remand could be ordered:

12Venue is proper in the District Court identified in Paragraph 11 because:

a substantial part of the events and omissions giving rise to Plaintiff(s)’ claims occurred there

Zionsville, IN South Carolina South Carolina Irmo, South Carolina United States District Court District of South Carolina

✔ ✔ other (plead in sufficient detail as required by applicable rules):

13If applicable, identify the citizenship of any additional Defendant(s) named above:

PRODUCT USE

14Plaintiff/Decedent used the following GLP-1 RA Product(s) for which claims are being asserted in this case (check all that apply):

Ozempic (semaglutide) Wegovy (semaglutide) Rybelsus (oral semaglutide) Victoza (liraglutide) Saxenda (liraglutide) Trulicity (dulaglutide) Mounjaro (tirzepatide) Zepbound (tirzepatide) Other(s) (specify):

15To the best of Plaintiff(s)’ knowledge, Plaintiff/Decedent used GLP-1 RA Product(s) during the following approximate date range(s) (month(s) and year(s)) (if multiple products, specify date range(s) for each product):

Approximately August 2022 through May 2024

✔

Read the full filing

You’re reading pages 1–5 of 11. Register free to read the complete 11-page transcript on this page.

These are public U.S. federal court records, available free from PACER and the court. Registration unlocks our full on-page transcript — a convenience service.

Public U.S. federal court record (district court docket 73106165, document 1). Source via the RECAP Archive (Free Law Project). The same record is available from PACER. Informational only — not legal advice.